Year: 2020
Type: dissertation
Abstract: Glioblastoma multiforme is an aggressive brain tumour characterized by poor prognosis, with overall patient survival rates averaging less than 15 months. Current treatment methods display immediate control of the disease, however treatment-resistant cell populations persevere, and disease recurrence is inevitable. As a result, all patients eventually succumb to the effects of their disease. Therefore, there is a need for therapeutic approaches that are capable of targeting the treatment-resistant cell populations in glioblastoma in order to provide patients their most meaningful period of remission. In this study, we propose that FDA-approved agents capable of crossing the blood-brain barrier can be repurposed for use in glioblastoma. In particular, the lipid-lowering agent lomitapide shows promising therapeutic potential in glioblastoma due to its ability to alter exogenous cholesterol levels, which Villa et al. have shown GBM cells rely on for survival.
Source: TSpace (University of Toronto)
Author: Taylor M. Wilson
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3143771595